Last update: March 29, 2015
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
At latest update, relevant published data on excretion into breast milk were not found.
A high protein-binding capacity makes excretion into breast milk unlikely. In addition, a low oral bioavailability makes difficult the absorption towards the infant's plasma from ingested milk, except in prematures or newborns who may show an increased absorption.
Case report of kidney function impairment of a baby whose mother had taken Telmisartan in pregnancy.
Until more data on this medication is available, safer alternative drugs are preferred, especially in premature babies or during the neonatal period.
Should an ARA-II medication (Sartan type) be necessary, the associated risk may be decreased by choosing the one with a favorable pharmacokinetics (shorter half-life elimination time and lower bioavailability) like Eprosartan and Losartan
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.